What is Hibercell?
Hibercell operates at the intersection of computational biology and traditional drug development. The company is dedicated to identifying and exploiting stress-induced vulnerabilities in malignant cells, a strategy that holds significant promise for patients who have exhausted standard treatment options. With a robust portfolio that includes clinical-stage candidates such as HC-7366, HC-5404, and Odetiglucan, Hibercell is systematically building a platform designed to disrupt the mechanisms of cancer survival. Their market position is reinforced by a leadership team of seasoned biotech executives who prioritize data-driven insights to accelerate the transition from laboratory discovery to clinical application, effectively bridging the gap between complex molecular biology and patient-centric care.
How much funding has Hibercell raised?
Hibercell has raised a total of $158.2M across 3 funding rounds:
Series A
$60.8M
Series B
$67.4M
Debt
$30M
Series A (2019): $60.8M with participation from 6 Dimensions Capital, Hillhouse Capital, Celgene Corporation, and ARCH Venture Partners
Series B (2021): $67.4M led by Magnetic Ventures, Tekla Healthcare Opportunities, ARCH Venture Partners, Monashee Investment Management, Huizenga Capital Management, Trinitas Capital Management, Mount Sinai Health System, Bristol-Myers Squibb, and Hercules Capital
Debt (2021): $30M supported by Hercules Capital
Key Investors in Hibercell
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations.
Bristol-Myers Squibb
A global biopharmaceutical organization dedicated to discovering and developing prescription medications that address serious patient needs across oncology, cardiovascular disease, and immunoscience.
Hercules Capital
Hercules Capital is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in the life sciences and technology sectors.
What's next for Hibercell?
The infusion of capital provides Hibercell with the necessary runway to accelerate its clinical development programs and expand its computational research capabilities. As the company matures, the focus will likely shift toward optimizing the delivery of its lead candidates and exploring potential synergistic combinations with existing immunotherapies. Given the high-caliber backing from institutional investors and strategic biopharmaceutical partners, Hibercell is well-positioned to navigate the complexities of late-stage clinical trials. Future milestones will center on demonstrating durable clinical efficacy and establishing a clear regulatory pathway for its novel therapeutic modalities, ultimately aiming to redefine the standard of care for patients facing treatment-resistant malignancies.
See full Hibercell company page
